Treatment characteristics according to prophylactic regimen
| . | Netherlands, intermediate-dose median (IQR)* . | Sweden, high-dose median (IQR)* . | P . |
|---|---|---|---|
| N | 78 | 50 | |
| Hemophilia A, n | 70 | 45 | 1.00 |
| Age at evaluation, y | 24.8 (19.3-30.2) | 23.2(18.7-28.0) | .47 |
| Weight, kg | 75 (64-85) | 73 (62-80) | .28 |
| Treatment history | |||
| Age at diagnosis, y | 0.7 (0.04-1.2) | 0.6 (0.3-0.9) | .55 |
| Age at 1st treatment, y | 1.1 (0.9-1.7) | 0.9 (0.5-1.2) | <.01 |
| Age at start prophylaxis, y | 4.5 (3.2-6.0) | 1.5 (1.1-2.5) | <.01 |
| Prophylaxis started before first joint bleed, n/N (%) | 6/69 (9%) | 19/45 (42%) | <.01 |
| Age at start of home treatment, y | 5.7 (3.9-9.3) | 3.3 (2.0-4.5) | <.01 |
| Treatment during the last 5 y | |||
| Full-time prophylaxis, n (%) | 61 (78) | 48 (96) | <.01 |
| Weekly dose, IU/kg | 46 (34-55) | 88 (61-113) | <.01 |
| Number of infusions/week | 3.0 (2.5-3.0) | 3.3 (1.6-3.5) | .19 |
| Annual consumption, IU/kg per year† | 2100 (1400-2900) | 4000 (3000-4900) | <.01 |
| . | Netherlands, intermediate-dose median (IQR)* . | Sweden, high-dose median (IQR)* . | P . |
|---|---|---|---|
| N | 78 | 50 | |
| Hemophilia A, n | 70 | 45 | 1.00 |
| Age at evaluation, y | 24.8 (19.3-30.2) | 23.2(18.7-28.0) | .47 |
| Weight, kg | 75 (64-85) | 73 (62-80) | .28 |
| Treatment history | |||
| Age at diagnosis, y | 0.7 (0.04-1.2) | 0.6 (0.3-0.9) | .55 |
| Age at 1st treatment, y | 1.1 (0.9-1.7) | 0.9 (0.5-1.2) | <.01 |
| Age at start prophylaxis, y | 4.5 (3.2-6.0) | 1.5 (1.1-2.5) | <.01 |
| Prophylaxis started before first joint bleed, n/N (%) | 6/69 (9%) | 19/45 (42%) | <.01 |
| Age at start of home treatment, y | 5.7 (3.9-9.3) | 3.3 (2.0-4.5) | <.01 |
| Treatment during the last 5 y | |||
| Full-time prophylaxis, n (%) | 61 (78) | 48 (96) | <.01 |
| Weekly dose, IU/kg | 46 (34-55) | 88 (61-113) | <.01 |
| Number of infusions/week | 3.0 (2.5-3.0) | 3.3 (1.6-3.5) | .19 |
| Annual consumption, IU/kg per year† | 2100 (1400-2900) | 4000 (3000-4900) | <.01 |